Form 4: GeneDx Holdings CEO Katherine Stueland Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
GeneDx Holdings CEO Katherine Stueland sold shares of Class A Common Stock on April 9, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Katherine Stueland, CEO of GeneDx Holdings Corp., sold shares of Class A Common Stock on April 9, 2025.
- The sales were executed under a Rule 10b5-1 trading plan adopted on August 16, 2024.
- A total of 41,814 shares were sold at varying weighted average prices ranging from $81.1573 to $97.2443 per share.
- Following the transactions, Stueland directly owns 1,720 shares of Class A Common Stock.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock sales under a pre-arranged plan. It doesn't necessarily indicate positive or negative sentiment about the company's future.
Industry Context
This filing is a routine disclosure of insider trading activity. It's common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The stock sale could have a minor negative impact on shareholder sentiment, although it's likely to be minimal given the pre-arranged nature of the sales.
Key Dates
| Date | Description |
|---|---|
| 08/16/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 04/09/2025 | Date of stock sale transactions |
| 04/10/2025 | Date of Form 4 filing |
Keywords
GeneDx Holdings Corp, Katherine Stueland, Form 4, SEC Filing, Stock Sale, Rule 10b5-1, WGS, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.